ANAPTYSBIO, INC — Form SCHEDULE 13D/A
Filed November 18, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 72/100
What the filing says
Between Nov 16–18, 2026, EcoR1 Capital, LLC and EcoR1 Capital Fund Qualified, L.P. (managed by Oleg Nodelman) purchased 374,580 shares of AnaptysBio at prices ranging from $45.65 to $46.54 per share, totaling approximately $17.4M. This represents a material stake-building exercise by the investment fund, with both entities filing jointly under Schedule 13D.
Why this rating
~$17.4M purchase (~4% of $432.5M market cap) signals significant investor confidence; material for position-building but no control shift yet. Scale warrants attention.
Price action (we called it neutral)
at our read · unknown $48.41 | +10 min · unknown $48.26 ▼ 0.32% | +30 min · unknown $47.47 ▼ 1.94% | +1 hr · unknown $47.75 ▼ 1.36% | +4 hrs · unknown $47.59 ▼ 1.69% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.